Tag - CYCC

Feature

Cyclacel translating cancer biology into potential medicines

Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as leukemia.

April 13, 2021

Markets

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

May 19, 2020

Tag - CYCC

Cyclacel translating cancer biology into potential medicines

Brookline starts Cyclacel Pharma at buy; PT $22

General

More